Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1OM8E
|
|||
| Drug Name |
AR1001
|
|||
| Synonyms |
N-METHYLBENZYLAMINE; 103-67-3; N-Benzylmethylamine; N-methyl-1-phenylmethanamine; Methylbenzylamine; Benzylmethylamine; Benzyl(methyl)amine; Benzenemethanamine, N-methyl-; N-Benzyl-N-methylamine; Benzylamine, N-methyl-; N-Methy-N-benzylamine; Benzyl-methyl-amine; N-methyl-N-benzylamine; methyl benzylamine; N-Methyl(phenyl)methanamine; BENZYLAMINE, N-METHYL; N-benzyl-methylamine; N-methyl benzylamine; N-methyl-N-(phenylmethyl)amine; Benzylmethyl-d3-amine; NSC 8059; N-methylbenzenemethanamine; MFCD00008289; N-methyl-1-phenyl-methanamine; 7KN7F4X49E; NSC-8059; methylbezylamine; benzyl methylamine; benzyl-methylamine; HNMeBzl; N-benzylmethanamine; benzyl methyl amine; methyl-benzyl amine; EINECS 203-133-4; N-benzyl methylamine; N-methyl-benzylamine; N-methylbenzyl amine; N-benzyl methyl amine; N-benzyl-methyl amine; N-methyl -benzylamine; N-methyl benzyl amine; N-methyl-benzyl amine; (-)-methylbenzylamine; Methylbenzylamine, N-; omega-Methylaminotoluene; Spectrum_001362; AI3-26793; Methyl(phenylmethyl)amine; N-benzyl-N-methyl-amine; N-methyl-N-benzyl amine; Spectrum4_001764; Spectrum5_000347; Racemic methylbenzyl amine; N-methyl-benzenemethanamine; EC 203-133-4; N-(Phenylmethyl)methylamine; N-Benzylmethylamine, 97%; SCHEMBL2271; CHEMBL1338; UNII-7KN7F4X49E; KBioGR_002247; KBioSS_001842; MLS004773900; DTXSID9048439; KBio2_001842; KBio2_004410; KBio2_006978; NSC8059; (+)-2-Methylbutylp-aminocinnamate; STR02536; AR1001; AKOS000119094; CS-W007426; HY-W007426; SDCCGMLS-0066901.P001; NCGC00166047-01; SMR000112361; FT-0631560; M0164; EN300-18191; W-108843; BRD-K44558320-003-01-7; Q23978278; Z57327124; F2190-0316; InChI=1/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 3 | [1] | |
| Company |
AriBio
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H11N
|
|||
| Canonical SMILES |
CNCC1=CC=CC=C1
|
|||
| InChI |
InChI=1S/C8H11N/c1-9-7-8-5-3-2-4-6-8/h2-6,9H,7H2,1H3
|
|||
| InChIKey |
RIWRFSMVIUAEBX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 5 (PDE5) | Target Info | Inhibitor | [2] |
| Phosphodiesterase 5 (PDE5) | Target Info | Inhibitor | [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05531526) A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants With Early Alzheimer's Disease (Polaris-AD). U.S.National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight | |||
| REF 3 | ClinicalTrials.gov (NCT03625622) A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.